NCT06023758View on ClinicalTrials.gov

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 22, 2023

Primary Completion Date

September 1, 2025

Study Completion Date

December 31, 2026

Conditions
HER2-positive Locally Advanced Resectable Gastric Cancer
Interventions
DRUG

KN026

KN026：30 mg/kg Q3W

DRUG

KN046

KN046：5 mg/kg Q3W

DRUG

XELOX

Oxaliplatin 130mg/m2 d1，Capecitabine 1000mg/m2 d1-14，Q3W

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University

OTHER